ライフサイエンスコーパス: overtreatment

1 ostate cancer mortality) and minimize costs (overtreatment).

2 tment threshold that is safe but also avoids overtreatment.

3 t outputs, but may significantly reduce NMFI overtreatment.

4 with moderate-dose statins while minimizing overtreatment.

5 carcinoma is not accurate enough to prevent overtreatment.

6 come symptomatic (overdiagnosis), leading to overtreatment.

7 apy decisions to improve outcomes and reduce overtreatment.

8 tantial potential risk for overdiagnosis and overtreatment.

9 ears to reduce the risk of PCSM with minimal overtreatment.

10 lives, there are growing concerns regarding overtreatment.

11 dard for confirming pCR-B, may be considered overtreatment.

12 lacing the public at risk of overtesting and overtreatment.

13 native therapy or who may be spared possible overtreatment.

14 ed, which could lead to delayed diagnosis or overtreatment.

15 lation may cause significant harm, including overtreatment.

16 w to balance the risks of undertreatment and overtreatment.

17 result in relatively high levels (~ 75%) of overtreatment.

18 iewed as a major driver of overdiagnosis and overtreatment.

19 til after multidisciplinary input may reduce overtreatment.

20 antibiotics must be weighed against risks of overtreatment.

21 dissection (ALND) may result in significant overtreatment.

22 , it leads to high rates of misdiagnosis and overtreatment.

23 potential harms, including overdiagnosis and overtreatment.

24 pt to new concepts to avoid misdiagnosis and overtreatment.

25 d no diagnostic benefit and may even lead to overtreatment.

26 atients with advanced cancer could result in overtreatment.

27 disease, and careful surveillance may avoid overtreatment.

28 tive value, which leads to overdiagnosis and overtreatment.

29 characterize the balancing measure of sepsis overtreatment.

30 isk subgroup was characterized to help avoid overtreatment.

31 imize TUS use and mitigate overdiagnosis and overtreatment.

32 ed for more shared decision making to reduce overtreatment.

33 cancer patients, particularly by preventing overtreatment.

34 issue mass after trauma to avoid unnecessary overtreatment.

35 for ongoing clinical efforts to reduce DCIS overtreatment.

36 lance and reduce prevalent overdiagnosis and overtreatment.

37 to follow-up but would result in substantial overtreatment.

38 and avoids the pitfall of undertreatment and overtreatment.

39 R metric for clinical surveillance of sepsis overtreatment.

40 ion-making, which can decrease the extent of overtreatment.

41 criteria and outcomes associated with sepsis overtreatment.

42 therefore all HGAIN is treated, resulting in overtreatment.

43 gular adjustments to avoid undertreatment or overtreatment.

44 tion about CPM is needed to reduce potential overtreatment.

45 identify indolent tumors are needed to avoid overtreatment.

46 ates of re-excision, radical resections, and overtreatment.

47 gement and ultimately increasing the risk of overtreatment.

48 ent infections while simultaneously limiting overtreatment.

49 e effects, and the risk of overdiagnosis and overtreatment.

50 has led to concerns about overdiagnosis and overtreatment.

51 y minimizing the inconveniences and costs of overtreatment.

52 d by screening, leading to overdiagnosis and overtreatment.

53 ncer has raised concerns about potential for overtreatment.

54 ticularly in women living with HIV, leads to overtreatment.

55 overdiagnosis and, if unrecognised, possible overtreatment.

56 ve malaria treatment without increasing NMFI overtreatment.

57 entify LNM-positive patients to prevent such overtreatments.

58 d with prostate cancer screening, other than overtreatment?

59 se is of utmost significance, as it prevents overtreatment and adverse effects in patients.

60 rapid investigation to minimize the risk of overtreatment and antibiotic-associated harms for patien

61 have serious negative consequences including overtreatment and associated complications, financial to

62 erplasia include avoidance of glucocorticoid overtreatment and control of sex hormone imbalances.

63 of (18)F-FET PET has the potential to avoid overtreatment and corresponding costs, as well as unnece

64 d-line radical cystectomy is associated with overtreatment and drastic lifestyle consequences.

65 ions have motivated lingering concerns about overtreatment and failure to involve women in treatment

66 se with heightened perception are at risk of overtreatment and iatrogenic adverse effects with reliev

67 state cancers (CaP) is important to decrease overtreatment and increase survival for men with the agg

68 indolent ones, thereby potentially avoiding overtreatment and its associated complications.

69 losis treatment, which indicates substantial overtreatment and limited undertreatment.

70 We quantified the incidence of antibiotic overtreatment and possible antibiotic-associated harms a

71 decision making is fundamental to preventing overtreatment and promoting high-value, individualized p

72 IS, including active surveillance, to reduce overtreatment and provide patients with more personalize

73 tial sepsis patients revealed a high rate of overtreatment and provides a useful tool to inform sepsi

74 s an appealing strategy for the reduction of overtreatment and secondary adverse effects.

75 further de-escalation of treatment, to avoid overtreatment and the risk of side effects.

76 to the individual patient to avoid not only overtreatment and treatment-related sequelae but also un

77 ble therapy for individuals and avoidance of overtreatment and undertreatment of patients with conven

78 bserver variability in grading can result in overtreatment and undertreatment of prostate cancer.

79 development of invasive SBC may help reduce overtreatment and undertreatment of women from minority

80 nding of cause-specific outcomes may lead to overtreatment and undertreatment.

81 Bias (a systemic deviation towards overtreatment) and noise (a random scatter) affect the d

82 me INSS stage 1 patients (1) are at risk for overtreatment, and (2) have poor-prognostic biologic fin

83 to individualize glycemic goals and prevent overtreatment, and can serve as a template for applying

84 biology will improve early detection, reduce overtreatment, and foster preventative therapies targeti

85 to guide salvage treatment decisions, reduce overtreatment, and limit the number of staging tests in

86 eutical marketing can lead to overdiagnosis, overtreatment, and overuse of medications.

87 to identify factors predictive of adherence, overtreatment, and undertreatment.

88 d cancers; the evidence of overdiagnosis and overtreatment; and provide overviews of existing interna

89 and indirect evidence that overdiagnosis and overtreatment are likely to be substantial with populati

90 The terms undertreatment and overtreatment are often used to describe inappropriate m

91 has resulted in overdiagnosis and consequent overtreatment as well as underdiagnosis and missed diagn

92 A key concern of DCIS is overtreatment, as most patients screened for DCIS and in

93 Screening also results in considerable overtreatment because many CIN2/3 lesions show spontaneo

94 To reduce overtreatment, biomarkers are needed to delineate advanc

95 : OR, 1.20; 95% CI, 1.06-1.36; P = .004) and overtreatment (Black patients: OR, 1.09; 95% CI, 1.05-1.

96 y transformative in reducing the significant overtreatment burden of this malignancy.

97 o a 35% decrease (95% UI:31.2-39.8%) in NMFI overtreatment, but also a 19.5% reduction (95% UI:11-27.

98 n important option to reduce prostate cancer overtreatment, but it remains underutilized in many coun

99 c stewardship can decrease overdiagnosis and overtreatment, but optimal implementation of such interv

100 nagement would have hypothetically decreased overtreatment by 94%, eliminating a median of 44 overtre

101 managing chronic inflammatory diseases where overtreatment can cause significant side effects.

102 surgeon-led initiatives to address potential overtreatment can reduce the burden of surgical manageme

103 is treatment paradigm has been challenged by overtreatment concerns and evidence that suggests that D

104 rising steadily because of overdiagnosis and overtreatment conferred by widespread use of sensitive i

105 ency and characteristics of patients meeting overtreatment criteria and outcomes associated with seps

106 Patients classified by the SEP-OS overtreatment criteria had higher median antibiotic days

107 le range, 43-47) per patient and 2,169 total overtreatment days (95% confidence interval, 1,938-2,400

108 treatment by 94%, eliminating a median of 44 overtreatment days (interquartile range, 43-47) per pati

109 g the new model to indicate aRT might reduce overtreatment, decrease unnecessary adverse effects, and

110 rtality; and harms, including overdiagnosis, overtreatment, diagnostic procedure-related harms, fear,

111 herapy and to monitor their response so that overtreatment does not completely abrogate host defense

112 with supplementary private insurance receive overtreatment due to financial incentives.

113 atal sepsis is the key driver for antibiotic overtreatment early in life.

114 To limit overtreatment, elderly individuals at truly low risk nee

115 nt controversies surrounding prostate cancer overtreatment emphasize the critical need to delineate t

116 In just 6 categories of waste--overtreatment, failures of care coordination, failures i

117 We examined possible overtreatment for patients >/=18 years of age by examini

118 to therapies that would otherwise result in overtreatment for some patients.

119 s to high-risk populations, while minimizing overtreatment for the rest.

120 guideline-based treatment (undertreatment or overtreatment) for kidney cancer, as defined by accepted

121 r, may come at the cost of low care quality (overtreatment) for low-risk prostate cancer.

122 rue disease, overtesting, overdiagnosis, and overtreatment have become common.

123 Despite efforts to reduce overtreatment, improve care, and address overpayment, it

124 my or radiation therapy has been shown to be overtreatment in 30% of patients.

125 risk factors was suboptimal and may lead to overtreatment in approximately 30% of patients.

126 iew found evidence of ADHD overdiagnosis and overtreatment in children and adolescents.

127 on-based assay with the potential to prevent overtreatment in low-risk disease.

128 ading to unnecessary and potentially harmful overtreatment in many patients.

129 recommendation for AC for pN2 disease may be overtreatment in most patients.

130 ptor-positive (HR+) breast cancer, potential overtreatment in older adults with frailty persists.

131 rategy could help to avoid overdiagnosis and overtreatment in patients with Barrett's oesophagus.

132 strategies may be beneficial, while avoiding overtreatment in patients with incurable disease.

133 reduce the number of invasive procedures and overtreatment in patients with treatment-related changes

134 quality of care, has the potential to halve overtreatment in public and mission health facilities in

135 The high rate of overtreatment in the population studied carries both fin

136 However, overtreatment in the see-and-treat strategy has been rep

137 To limit overtreatment in these cases, minimally invasive limited

138 ons fell in the lower range, with no sign of overtreatment in these patients.

139 dence of toxicities, and limit the extent of overtreatment in this population.

140 nefit from neo-adjuvant therapy and to avoid overtreatment in those patients who can proceed directly

141 equently leads to inappropriate stenting and overtreatment in up to one-third of patients and the ass

142 AS represents a strategy to mitigate overtreatment in young patients with low-risk PCa in the

143 Overtreatment, in an attempt to reduce symptoms, can be

144 gressive, existing practice often results in overtreatment including unnecessary surgeries that degra

145 Overdetection and overtreatment is common in many areas of modern medicine

146 he US, understanding the negative effects of overtreatment is critical to help guide prescribing prac

147 hypothyroidism, beyond QOL, and the risks of overtreatment is imperative.

148 Overtreatment is pervasive in medicine and leads to pote

149 Overtreatment is therefore a major issue, demanding new

150 ximizing screening efficacy while minimizing overtreatment is vital, especially when considering how

151 Overtreatment may be a growing problem, especially among

152 Hereby, substantial surgical overtreatment may be avoided, leading to treatment optim

153 Overtreatment most commonly implied intensive treatment

154 es using the terms undertreatment (n = 236), overtreatment (n = 71), or both (n = 51) met criteria fo

155 Range of overtreatment narrowed to 4.0-23.5% for those with norma

156 life expectancy is challenging, but surgical overtreatment needs to be prevented.

157 s more aggressive lymphomas, causing patient overtreatment, needs also to be considered.

158 The adverse effects of overdiagnosis and overtreatment observed in men with clinically insignific

159 On the basis of concerns regarding overtreatment of biologically indolent cancers, focal ab

160 tifying children with malaria, and that much overtreatment of children without parasitaemia could be

161 rsial because it increases overdiagnosis and overtreatment of clinically insignificant tumors.

162 opathologic factors (CPF) contributes to the overtreatment of DCIS.

163 may provide an opportunity to further reduce overtreatment of disease that is unlikely to progress to

164 Recent recognition of the overdiagnosis and overtreatment of ductal carcinoma in situ (DCIS) detecte

165 Conversely, overtreatment of false positive bacteriuria could lead t

166 e most adequate treatment, thus avoiding the overtreatment of frail patients and the undertreatment o

167 Overtreatment of heparin-induced thrombocytopenia in the

168 ntify HGAIN in need of treatment, preventing overtreatment of HGAIN with a low cancer progression ris

169 tication of PCa course can be performed, and overtreatment of indolent cancer can be avoided.

170 s what information will be needed to prevent overtreatment of indolent DCIS lesions without compromis

171 Overtreatment of indolent disease also results in signif

172 clinically significant disease and potential overtreatment of indolent disease.

173 ce early detection of aggressive disease and overtreatment of indolent disease.

174 prostate cancer (PC) are suboptimal, causing overtreatment of indolent PC and risk of delayed treatme

175 to guide clinical decision-making and avoid overtreatment of indolent PC and undertreatment of aggre

176 clinical trajectory frequently leads to both overtreatment of indolent processes and delayed treatmen

177 Overdiagnosis and overtreatment of indolent prostate cancer (PCA) is a ser

178 ly adverse high-risk tumors while minimizing overtreatment of indolent, low-risk tumors.

179 Overdiagnosis and overtreatment of LB is worsening.

180 eatment selection, but the data suggest both overtreatment of low-risk disease and undertreatment of

181 stratification are urgently needed to avoid overtreatment of low-risk patients and to prioritize alt

182 l quality indicator is essential to minimize overtreatment of low-risk prostate cancer and by extensi

183 Overdiagnosis and overtreatment of Lyme disease are associated with inappr

184 nsequences associated with overdiagnosis and overtreatment of Lyme disease, although previously recog

185 as been proposed as an approach for reducing overtreatment of malaria in the current era of widesprea

186 fer multiagent therapy upfront, resulting in overtreatment of many patients.

187 according to an algorithm designed to avoid overtreatment of mild disease and to accelerate treatmen

188 es treated with ACT, but also an increase in overtreatment of NMFI, with 70% NMFI cases (95% UI:56.4-

189 rates, but it may increase overdiagnosis and overtreatment of nonneoplastic polyps.

190 Undertreatment and overtreatment of older adults with cancer are imprecisel

191 y clinicians could reduce undertreatment and overtreatment of older children and adults with acute di

192 s causing a high degree of overdiagnosis and overtreatment of otherwise clinically insignificant case

193 t because of high rates of overdiagnosis and overtreatment of otherwise indolent tumors.

194 ing a therapeutic algorithm may lead to less overtreatment of patients and cost savings.

195 Awareness of the potential global overtreatment of patients with appendiceal neuroendocrin

196 cancer will develop metastases leads to the overtreatment of patients with benign disease and to the

197 Overtreatment of patients with ductal carcinoma in situ

198 s also led to overdiagnosis and consequently overtreatment of patients with low-risk disease.

199 This can lead to overtreatment of patients, resulting in an increased ris

200 eliable, which contributes to the under- and overtreatment of patients.

201 of a time frame for reevaluation lead to the overtreatment of patients?

202 screening results to avoid misdiagnosis and overtreatment of persons with isolated clinic hypertensi

203 men's perspectives lead to overdiagnosis and overtreatment of prolonged labour

204 ecific antigen screening has led to enormous overtreatment of prostate cancer because of the inabilit

205 techniques also results in overdiagnosis and overtreatment of so-called silent stroke.

206 causes long-term toxicity and may represent overtreatment of some patients.

207 atment, potentially causing misdiagnosis and overtreatment of STIs.

208 der to prevent undertreatment of disease and overtreatment of suspects.

209 -effectiveness and data addressing potential overtreatment of suspicious skin lesions.

210 ancer that has resulted in overdiagnosis and overtreatment of the disease.

211 improved survival, thereby avoiding systemic overtreatment of these patients.

212 urgently needed to reduce overdiagnosis and overtreatment of this common disease.

213 hest risk of malignant progression and avoid overtreatment of those with low-risk disease.

214 ch patients while avoiding overdiagnosis and overtreatment of those with slow-growing, indolent tumou

215 h issues of overdiagnosis and the consequent overtreatment of thyroid cancer.

216 recommendations regarding overdiagnosis and overtreatment of thyroid nodules and low-risk papillary

217 At the same time, overtreatment of uninfected individuals increases the ri

218 re is costly, and decedents often experience overtreatment or low-quality care.

219 oordination, $29.6 billion to $38.2 billion; overtreatment or low-value care, $12.8 billion to $28.6

220 oordination, $27.2 billion to $78.2 billion; overtreatment or low-value care, $75.7 billion to $101.2

221 care delivery, failure of care coordination, overtreatment or low-value care, pricing failure, fraud

222 erity of illness and mortality risk, whereas overtreatment or undertreatment (relative to the individ

223 Significant overtreatment or undertreatment (relative to the optimal

224 Older adults with cancer are at risk of overtreatment or undertreatment when decision-making is

225 atment intensity over time in order to avoid overtreatment or undertreatment, and the use of supporti

226 ce the thyrotropin level is at goal to avoid overtreatment or undertreatment, both of which are assoc

227 9-3.01; P < .001) and lower adjusted odds of overtreatment (OR, 0.72; 95% CI, 0.67-0.77; P < .001).

228 -0.88; P < .001) and higher adjusted odds of overtreatment (OR, 1.27; 95% CI, 1.24-1.30; P < .001) co

229 DL <100 mg/dL) had higher rates of potential overtreatment (P<0.001).

230 erformance at finding infections, minimizing overtreatment, reducing clinical case counts, and interr

231 he tuberculosis burden, although concerns of overtreatment remain because of false positive diagnoses

232 To address this potential overtreatment, sentinel lymph node (SLN) biopsy is curre

233 Decision support efforts to address overtreatment should target regions with low rates of ev

234 ecord (EHR) data-derived criteria for sepsis overtreatment surveillance (SEP-OS).

235 ment, reducing pCRM involvement and avoiding overtreatment through selective preoperative therapy and

236 f all potential organisms, carrying risks of overtreatment, toxicity, and selection of multidrug-resi

237 ert Ultra will likely result in considerable overtreatment unless the possibility of higher specifici

238 AT programs need to weigh trade-offs between overtreatment versus delayed or no treatment for women w

239 eligible patients, the prevalence of sepsis overtreatment was 22.5%.

240 l or low-grade pathology when calculation of overtreatment was restricted to patients diagnosed with

241 Definitions of undertreatment and overtreatment were extracted, and categories underlying

242 Reductions in overtreatment were sustained and without negative impact

243 as lower (with a possibility of no increased overtreatment) when using specificity data only from low

244 persistent high rates of mastectomy suggest overtreatment, whereas lower than expected rates of radi

245 ment to meet the clinical need for resolving overtreatment, which continues to be a pervasive problem

246 te balance between high cancer cure rate and overtreatment, which could potentially lead to unnecessa

247 Here, we discuss the potential problem of overtreatment with anti-PD-1 directed agents in general

248 Thus, overtreatment with antibiotics is widely prevalent, but

249 nomatous germ cell tumors (NSGCTs) to reduce overtreatment with chemotherapy.

250 ersistent use of BCG despite recurrence, and overtreatment with early cystectomy.

251 only a treat-to-target approach may motivate overtreatment with high-dose statins, potentially leadin

252 These trends suggest that overtreatment with multiple inotropes contributes to the

253 ts that included the terms undertreatment or overtreatment with regard to older adults with cancer.

254 , presumptive treatment leads to substantial overtreatment without additional morbidity reduction und

255 sults, universal screening may cause initial overtreatment without reducing the rates of late detecti